Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyTerbutaline
Identification
- Name
- Terbutaline
- Accession Number
- DB00871 (APRD00589)
- Type
- Small Molecule
- Groups
- Approved
- Description
A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. [PubChem]
- Structure
Structure for DB00871 (Terbutaline)
- Synonyms
- Terbutalin
- Terbutalina
- Terbutaline (sulfate de)
- Terbutalini sulfas
- Terbutalinsulfat
- Terbutalinum
- External IDs
- KWD 2019
- Product Ingredients
Ingredient UNII CAS InChI Key Terbutaline Sulfate 576PU70Y8E 23031-32-5 MUPQZWGSBCWCAV-UHFFFAOYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Bricanyl Tab 2.5 mg Tablet 2.5 mg Oral Astra Zeneca 1978-12-31 2000-07-20 Canada 
Bricanyl Tab 5 mg Tablet 5 mg Oral Astra Zeneca 1975-12-31 2001-07-23 Canada Bricanyl Turbuhaler Powder, metered 0.5 mg Respiratory (inhalation) Astra Zeneca 1990-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Terbutaline Sulfate Tablet 2.5 mg/1 Oral State of Florida DOH Central Pharmacy 2009-07-01 Not applicable US 
Terbutaline Sulfate Injection 1 mg/mL Subcutaneous West Ward Pharmaceutical 2009-05-20 Not applicable US Terbutaline Sulfate Injection, solution 1 mg/mL Subcutaneous General Injectables & Vaccines 2011-11-16 Not applicable US Terbutaline Sulfate Tablet 2.5 mg/1 Oral Rebel Distributors 2005-03-25 Not applicable US Terbutaline Sulfate Injection 1 mg/mL Subcutaneous United Biomedical Inc., Asia 2014-12-15 Not applicable US Terbutaline Sulfate Tablet 5 mg/1 Oral Amerincan Health Packaging 2008-03-12 2016-01-01 US Terbutaline Sulfate Tablet 2.5 mg/1 Oral Av Kare, Inc. 2001-06-26 2015-12-29 US Terbutaline Sulfate Tablet 2.5 mg/1 Oral Lannett Company, Inc. 2005-03-25 Not applicable US Terbutaline Sulfate Tablet 5 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 2005-03-25 Not applicable US 
Terbutaline Sulfate Tablet 2.5 mg/1 Oral Red Pharm Drug, Inc. 2005-03-25 Not applicable US - International/Other Brands
- Brethaire (Novartis) / Brethine / Bricanyl (AstraZeneca) / Bricardyl (Johnson) / Bricasma (AstraZeneca) / Bricasol (AstraZeneca) / Dracanyl (AstraZeneca) / Terbasmin (AstraZeneca)
- Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Adrenergics for Systemic Use
- Agents to Treat Airway Disease
- Alcohols
- Amines
- Amino Alcohols
- Anti-Asthmatic Agents
- Autonomic Agents
- Beta2 Agonists
- Bronchodilator Agents
- Drugs for Obstructive Airway Diseases
- Ethanol
- Ethanolamines
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying)
- Reproductive Control Agents
- Respiratory System Agents
- Selective Beta 2-adrenergic Agonists
- Selective Beta-2-Adrenoreceptor Agonists
- Sympathomimetics
- Tocolytic Agents
- UNII
- N8ONU3L3PG
- CAS number
- 23031-25-6
- Weight
- Average: 225.2842
Monoisotopic: 225.136493479 - Chemical Formula
- C12H19NO3
- InChI Key
- XWTYSIMOBUGWOL-UHFFFAOYSA-N
- InChI
- InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
- IUPAC Name
- 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
- SMILES
- CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1
Pharmacology
- Indication
For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.
- Structured Indications
- Pharmacodynamics
Terbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation.
- Mechanism of action
The pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Target Actions Organism ABeta-2 adrenergic receptor agonistHuman UBeta-3 adrenergic receptor agonistHuman UBeta-1 adrenergic receptor antagonistHuman - Absorption
Approximately 30-50% if administered orally and well absorbed subcutaneously.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug. It appears that the sulfate conjugate is a major metabolite of terbutaline and urinary excretion is the primary route of elimination
- Half life
5.5-5.9 hours
- Clearance
- 311 +/- 112 mL/min
- Toxicity
Terbutaline Sulfate: Oral LD50(rat) = 8.7 g/kg; Oral LD50(mouse) = 205 mg/kg; Oral LD50(dog) = 1.5 g/kg; IP LD50(rat)= 220 mg/kg ; IP LD50(mouse) = 130 mg/kg; Oral LD50(rabbit) = >8 g/kg; IV LD50(mouse) = 36 mg/kg; IV LD50(dog) = 116 mg/kg; IV LD50(rabbit) = 110 mg/kg
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Terbutaline. Experimental Acebutolol The risk or severity of adverse effects can be increased when Terbutaline is combined with Acebutolol. Approved, Investigational Acemetacin The therapeutic efficacy of Acemetacin can be decreased when used in combination with Terbutaline. Approved, Experimental, Investigational Alfuzosin Alfuzosin may decrease the vasoconstricting activities of Terbutaline. Approved, Investigational Alprenolol Alprenolol may decrease the bronchodilatory activities of Terbutaline. Approved, Withdrawn Amineptine The risk or severity of adverse effects can be increased when Amineptine is combined with Terbutaline. Illicit, Withdrawn Amiodarone Terbutaline may increase the QTc-prolonging activities of Amiodarone. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Terbutaline. Approved Amoxapine The therapeutic efficacy of Terbutaline can be decreased when used in combination with Amoxapine. Approved Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Terbutaline. Approved, Illicit, Investigational Anagrelide Terbutaline may increase the QTc-prolonging activities of Anagrelide. Approved Arsenic trioxide Terbutaline may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Terbutaline may increase the QTc-prolonging activities of Artemether. Approved Asenapine Terbutaline may increase the QTc-prolonging activities of Asenapine. Approved Atenolol Atenolol may decrease the bronchodilatory activities of Terbutaline. Approved Atomoxetine Atomoxetine may increase the hypertensive activities of Terbutaline. Approved Atosiban The risk or severity of adverse effects can be increased when Terbutaline is combined with Atosiban. Approved, Investigational Azithromycin Terbutaline may increase the QTc-prolonging activities of Azithromycin. Approved Azosemide Terbutaline may increase the hypokalemic activities of Azosemide. Investigational Bedaquiline Terbutaline may increase the QTc-prolonging activities of Bedaquiline. Approved Bendroflumethiazide Terbutaline may increase the hypokalemic activities of Bendroflumethiazide. Approved Benmoxin The risk or severity of adverse effects can be increased when Benmoxin is combined with Terbutaline. Withdrawn Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Terbutaline. Approved, Illicit Benzylpenicilloyl Polylysine Terbutaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Betahistine The therapeutic efficacy of Terbutaline can be decreased when used in combination with Betahistine. Approved, Investigational Betaxolol Betaxolol may decrease the bronchodilatory activities of Terbutaline. Approved, Investigational Bisoprolol Bisoprolol may decrease the bronchodilatory activities of Terbutaline. Approved Bopindolol Bopindolol may decrease the bronchodilatory activities of Terbutaline. Approved Brofaromine The risk or severity of adverse effects can be increased when Brofaromine is combined with Terbutaline. Experimental Bromocriptine Bromocriptine may increase the hypertensive and vasoconstricting activities of Terbutaline. Approved, Investigational Bucindolol The risk or severity of adverse effects can be increased when Terbutaline is combined with Bucindolol. Investigational Bumetanide Terbutaline may increase the hypokalemic activities of Bumetanide. Approved Bunazosin Bunazosin may decrease the vasoconstricting activities of Terbutaline. Investigational Bupranolol Bupranolol may decrease the bronchodilatory activities of Terbutaline. Approved Cabergoline Cabergoline may increase the hypertensive and vasoconstricting activities of Terbutaline. Approved Calcium carbimide The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Terbutaline. Approved, Withdrawn Caroxazone The risk or severity of adverse effects can be increased when Caroxazone is combined with Terbutaline. Withdrawn Carteolol Carteolol may decrease the bronchodilatory activities of Terbutaline. Approved Carvedilol Carvedilol may decrease the vasoconstricting activities of Terbutaline. Approved, Investigational Celiprolol The risk or severity of adverse effects can be increased when Terbutaline is combined with Celiprolol. Approved, Investigational Ceritinib Terbutaline may increase the QTc-prolonging activities of Ceritinib. Approved Chloroquine Terbutaline may increase the QTc-prolonging activities of Chloroquine. Approved, Investigational, Vet Approved Chlorothiazide Terbutaline may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorphentermine The risk or severity of adverse effects can be increased when Terbutaline is combined with Chlorphentermine. Illicit, Withdrawn Chlorpromazine Terbutaline may increase the QTc-prolonging activities of Chlorpromazine. Approved, Investigational, Vet Approved Chlorthalidone Terbutaline may increase the hypokalemic activities of Chlorthalidone. Approved Ciprofloxacin Terbutaline may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cisapride Terbutaline may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Citalopram Terbutaline may increase the QTc-prolonging activities of Citalopram. Approved Clarithromycin Terbutaline may increase the QTc-prolonging activities of Clarithromycin. Approved Clenbuterol The risk or severity of adverse effects can be increased when Terbutaline is combined with Clenbuterol. Approved, Investigational, Vet Approved Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Terbutaline. Approved, Investigational, Vet Approved Cloranolol Cloranolol may decrease the bronchodilatory activities of Terbutaline. Experimental Clozapine Terbutaline may increase the QTc-prolonging activities of Clozapine. Approved Crizotinib Terbutaline may increase the QTc-prolonging activities of Crizotinib. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Terbutaline. Approved Cyclopenthiazide Terbutaline may increase the hypokalemic activities of Cyclopenthiazide. Experimental Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline. Approved, Investigational Desvenlafaxine Desvenlafaxine may increase the tachycardic activities of Terbutaline. Approved, Investigational Dibenzepin The risk or severity of adverse effects can be increased when Dibenzepin is combined with Terbutaline. Experimental Dihydroergotamine Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Terbutaline. Approved, Investigational Disopyramide Terbutaline may increase the QTc-prolonging activities of Disopyramide. Approved Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Terbutaline. Approved Dofetilide Terbutaline may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dolasetron Terbutaline may increase the QTc-prolonging activities of Dolasetron. Approved, Investigational Domperidone Terbutaline may increase the QTc-prolonging activities of Domperidone. Approved, Investigational, Vet Approved Dopamine The risk or severity of adverse effects can be increased when Terbutaline is combined with Dopamine. Approved Dosulepin The risk or severity of adverse effects can be increased when Dosulepin is combined with Terbutaline. Approved Doxazosin Doxazosin may decrease the vasoconstricting activities of Terbutaline. Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Terbutaline. Approved, Investigational Doxofylline The risk or severity of adverse effects can be increased when Doxofylline is combined with Terbutaline. Approved, Investigational Dronabinol Dronabinol may increase the tachycardic activities of Terbutaline. Approved, Illicit Dronedarone Terbutaline may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Terbutaline may increase the QTc-prolonging activities of Droperidol. Approved, Vet Approved Duloxetine Duloxetine may increase the tachycardic activities of Terbutaline. Approved Eliglustat Terbutaline may increase the QTc-prolonging activities of Eliglustat. Approved Epanolol The risk or severity of adverse effects can be increased when Terbutaline is combined with Epanolol. Experimental Ephedrine The risk or severity of adverse effects can be increased when Terbutaline is combined with Ephedrine. Approved Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Terbutaline. Approved, Vet Approved Epitizide Terbutaline may increase the hypokalemic activities of Epitizide. Experimental Ergoloid mesylate Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Terbutaline. Approved Ergonovine Ergonovine may increase the hypertensive and vasoconstricting activities of Terbutaline. Approved Ergotamine Ergotamine may increase the hypertensive and vasoconstricting activities of Terbutaline. Approved Erythromycin Terbutaline may increase the QTc-prolonging activities of Erythromycin. Approved, Investigational, Vet Approved Escitalopram Terbutaline may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational Esmirtazapine The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Terbutaline. Investigational Esmolol Esmolol may decrease the bronchodilatory activities of Terbutaline. Approved Etacrynic acid Terbutaline may increase the hypokalemic activities of Etacrynic acid. Approved, Investigational Etilefrine The risk or severity of adverse effects can be increased when Terbutaline is combined with Etilefrine. Withdrawn Fenoterol The risk or severity of adverse effects can be increased when Terbutaline is combined with Fenoterol. Approved, Investigational Fenozolone The risk or severity of adverse effects can be increased when Terbutaline is combined with Fenozolone. Experimental Flecainide Terbutaline may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Fluoxetine Terbutaline may increase the QTc-prolonging activities of Fluoxetine. Approved, Vet Approved Flupentixol Terbutaline may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Furazolidone The risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline. Approved, Investigational, Vet Approved Furosemide Terbutaline may increase the hypokalemic activities of Furosemide. Approved, Vet Approved Gadobenic acid Terbutaline may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Gemifloxacin Terbutaline may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Goserelin Terbutaline may increase the QTc-prolonging activities of Goserelin. Approved Granisetron Terbutaline may increase the QTc-prolonging activities of Granisetron. Approved, Investigational Haloperidol Terbutaline may increase the QTc-prolonging activities of Haloperidol. Approved Harmaline The risk or severity of adverse effects can be increased when Harmaline is combined with Terbutaline. Experimental Hydracarbazine The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Terbutaline. Experimental Hydrochlorothiazide Terbutaline may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Terbutaline may increase the hypokalemic activities of Hydroflumethiazide. Approved, Investigational Hydroxyamphetamine The risk or severity of adverse effects can be increased when Terbutaline is combined with Hydroxyamphetamine. Approved Ibutilide Terbutaline may increase the QTc-prolonging activities of Ibutilide. Approved Iloperidone Terbutaline may increase the QTc-prolonging activities of Iloperidone. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Terbutaline. Approved Indapamide Terbutaline may increase the hypokalemic activities of Indapamide. Approved Indoramin Indoramin may decrease the vasoconstricting activities of Terbutaline. Withdrawn Iobenguane The therapeutic efficacy of Iobenguane can be decreased when used in combination with Terbutaline. Approved, Investigational Iprindole The risk or severity of adverse effects can be increased when Iprindole is combined with Terbutaline. Experimental Iproclozide The risk or severity of adverse effects can be increased when Iproclozide is combined with Terbutaline. Withdrawn Iproniazid The risk or severity of adverse effects can be increased when Iproniazid is combined with Terbutaline. Withdrawn Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terbutaline. Approved Isoprenaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline. Approved, Investigational Isoxsuprine The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoxsuprine. Approved, Withdrawn Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Terbutaline. Approved Lacidipine Terbutaline may increase the hypotensive activities of Lacidipine. Approved, Investigational Lenvatinib Terbutaline may increase the QTc-prolonging activities of Lenvatinib. Approved, Investigational Leuprolide Terbutaline may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levofloxacin Terbutaline may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Levomilnacipran Levomilnacipran may increase the tachycardic activities of Terbutaline. Approved, Investigational Linezolid Linezolid may increase the hypertensive activities of Terbutaline. Approved, Investigational Lofepramine The risk or severity of adverse effects can be increased when Lofepramine is combined with Terbutaline. Experimental Lopinavir Terbutaline may increase the QTc-prolonging activities of Lopinavir. Approved Lorpiprazole The therapeutic efficacy of Terbutaline can be increased when used in combination with Lorpiprazole. Approved Lumefantrine Terbutaline may increase the QTc-prolonging activities of Lumefantrine. Approved Mebanazine The risk or severity of adverse effects can be increased when Mebanazine is combined with Terbutaline. Withdrawn Mefenorex The risk or severity of adverse effects can be increased when Terbutaline is combined with Mefenorex. Experimental Mephentermine The risk or severity of adverse effects can be increased when Terbutaline is combined with Mephentermine. Approved Mepindolol Mepindolol may decrease the bronchodilatory activities of Terbutaline. Experimental Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Terbutaline. Approved, Investigational Methadone Terbutaline may increase the QTc-prolonging activities of Methadone. Approved Methamphetamine The risk or severity of adverse effects can be increased when Terbutaline is combined with Methamphetamine. Approved, Illicit Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Terbutaline. Approved, Investigational Methyclothiazide Terbutaline may increase the hypokalemic activities of Methyclothiazide. Approved Methylene blue The risk or severity of adverse effects can be increased when Methylene blue is combined with Terbutaline. Approved, Investigational Methylergometrine Methylergometrine may increase the hypertensive and vasoconstricting activities of Terbutaline. Approved Metolazone Terbutaline may increase the hypokalemic activities of Metolazone. Approved Metoprolol Metoprolol may decrease the bronchodilatory activities of Terbutaline. Approved, Investigational Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Terbutaline. Approved Mifepristone Mifepristone may increase the QTc-prolonging activities of Terbutaline. Approved, Investigational Milnacipran Milnacipran may increase the tachycardic activities of Terbutaline. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Terbutaline. Approved Mirtazapine The risk or severity of adverse effects can be increased when Mirtazapine is combined with Terbutaline. Approved Moclobemide The risk or severity of adverse effects can be increased when Moclobemide is combined with Terbutaline. Approved, Investigational Moxifloxacin Terbutaline may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Nabilone Nabilone may increase the tachycardic activities of Terbutaline. Approved, Investigational Nebivolol Nebivolol may decrease the bronchodilatory activities of Terbutaline. Approved, Investigational Nialamide The risk or severity of adverse effects can be increased when Nialamide is combined with Terbutaline. Withdrawn Nilotinib Terbutaline may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Terbutaline. Approved Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Terbutaline. Approved Nylidrin The risk or severity of adverse effects can be increased when Terbutaline is combined with Nylidrin. Approved Octamoxin The risk or severity of adverse effects can be increased when Octamoxin is combined with Terbutaline. Withdrawn Ofloxacin Terbutaline may increase the QTc-prolonging activities of Ofloxacin. Approved Ondansetron Terbutaline may increase the QTc-prolonging activities of Ondansetron. Approved Opipramol The risk or severity of adverse effects can be increased when Opipramol is combined with Terbutaline. Investigational Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Terbutaline. Approved Oxprenolol Oxprenolol may decrease the bronchodilatory activities of Terbutaline. Approved Oxymetazoline The risk or severity of adverse effects can be increased when Terbutaline is combined with Oxymetazoline. Approved, Investigational Paliperidone Terbutaline may increase the QTc-prolonging activities of Paliperidone. Approved Panobinostat Terbutaline may increase the QTc-prolonging activities of Panobinostat. Approved, Investigational Pargyline The risk or severity of adverse effects can be increased when Pargyline is combined with Terbutaline. Approved Pazopanib Terbutaline may increase the QTc-prolonging activities of Pazopanib. Approved Penbutolol Penbutolol may decrease the bronchodilatory activities of Terbutaline. Approved, Investigational Pentamidine Terbutaline may increase the QTc-prolonging activities of Pentamidine. Approved, Investigational Perflutren Terbutaline may increase the QTc-prolonging activities of Perflutren. Approved Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Terbutaline. Approved Pheniprazine The risk or severity of adverse effects can be increased when Pheniprazine is combined with Terbutaline. Withdrawn Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Terbutaline. Approved, Illicit Phenoxypropazine The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Terbutaline. Withdrawn Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Terbutaline. Approved, Illicit Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Terbutaline. Approved Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Terbutaline. Approved, Vet Approved, Withdrawn Pimozide Terbutaline may increase the QTc-prolonging activities of Pimozide. Approved Piretanide Terbutaline may increase the hypokalemic activities of Piretanide. Approved Pirlindole The risk or severity of adverse effects can be increased when Pirlindole is combined with Terbutaline. Approved Pivhydrazine The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Terbutaline. Withdrawn Polythiazide Terbutaline may increase the hypokalemic activities of Polythiazide. Approved Prazosin Prazosin may decrease the vasoconstricting activities of Terbutaline. Approved Prenalterol The risk or severity of adverse effects can be increased when Terbutaline is combined with Prenalterol. Experimental Primaquine Terbutaline may increase the QTc-prolonging activities of Primaquine. Approved Procainamide Terbutaline may increase the QTc-prolonging activities of Procainamide. Approved Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Terbutaline. Approved, Investigational Procaterol The risk or severity of adverse effects can be increased when Terbutaline is combined with Procaterol. Approved, Investigational Promazine Terbutaline may increase the QTc-prolonging activities of Promazine. Approved, Vet Approved Propafenone Terbutaline may increase the QTc-prolonging activities of Propafenone. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline. Approved Pseudoephedrine The risk or severity of adverse effects can be increased when Terbutaline is combined with Pseudoephedrine. Approved Quetiapine Terbutaline may increase the QTc-prolonging activities of Quetiapine. Approved Quinethazone Terbutaline may increase the hypokalemic activities of Quinethazone. Approved Quinidine Terbutaline may increase the QTc-prolonging activities of Quinidine. Approved, Investigational Quinine Terbutaline may increase the QTc-prolonging activities of Quinine. Approved Racepinephrine The risk or severity of adverse effects can be increased when Terbutaline is combined with Racepinephrine. Approved Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Terbutaline. Approved Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline. Approved, Investigational Safrazine The risk or severity of adverse effects can be increased when Safrazine is combined with Terbutaline. Withdrawn Saquinavir Terbutaline may increase the QTc-prolonging activities of Saquinavir. Approved, Investigational Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Terbutaline. Approved, Investigational, Vet Approved Silodosin Silodosin may decrease the vasoconstricting activities of Terbutaline. Approved Sotalol Terbutaline may increase the QTc-prolonging activities of Sotalol. Approved Spironolactone Spironolactone may decrease the vasoconstricting activities of Terbutaline. Approved Sulfisoxazole Terbutaline may increase the QTc-prolonging activities of Sulfisoxazole. Approved, Vet Approved Synephrine The risk or severity of adverse effects can be increased when Terbutaline is combined with Synephrine. Experimental Tamsulosin Tamsulosin may decrease the vasoconstricting activities of Terbutaline. Approved, Investigational Tedizolid Phosphate Tedizolid Phosphate may increase the hypertensive activities of Terbutaline. Approved Telavancin Terbutaline may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin Terbutaline may increase the QTc-prolonging activities of Telithromycin. Approved Terazosin Terazosin may decrease the vasoconstricting activities of Terbutaline. Approved Tertatolol Tertatolol may decrease the bronchodilatory activities of Terbutaline. Experimental Tetrabenazine Terbutaline may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Tetryzoline The risk or severity of adverse effects can be increased when Terbutaline is combined with Tetryzoline. Approved Thioridazine Terbutaline may increase the QTc-prolonging activities of Thioridazine. Approved, Withdrawn Tianeptine The risk or severity of adverse effects can be increased when Tianeptine is combined with Terbutaline. Approved, Investigational Toloxatone The risk or severity of adverse effects can be increased when Toloxatone is combined with Terbutaline. Approved Torasemide Terbutaline may increase the hypokalemic activities of Torasemide. Approved Toremifene Terbutaline may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Tramazoline The risk or severity of adverse effects can be increased when Terbutaline is combined with Tramazoline. Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline. Approved, Investigational Tretoquinol The risk or severity of adverse effects can be increased when Terbutaline is combined with Tretoquinol. Experimental Trichlormethiazide Terbutaline may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Trimazosin Trimazosin may decrease the vasoconstricting activities of Terbutaline. Experimental Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Terbutaline. Approved Tyramine The risk or severity of adverse effects can be increased when Terbutaline is combined with Tyramine. Investigational, Nutraceutical Urapidil Urapidil may decrease the vasoconstricting activities of Terbutaline. Investigational Vandetanib Terbutaline may increase the QTc-prolonging activities of Vandetanib. Approved Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Terbutaline. Approved Venlafaxine Venlafaxine may increase the tachycardic activities of Terbutaline. Approved Ziprasidone Terbutaline may increase the QTc-prolonging activities of Ziprasidone. Approved Zuclopenthixol Terbutaline may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Alison B. Lukacsko, Joseph J. Piala, "Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions." U.S. Patent US5260333, issued December, 1983.
US5260333- General References
- Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, Slotkin TA: Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10. [PubMed:14610225]
- Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [PubMed:1358833]
- Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [PubMed:2062329]
- External Links
- Human Metabolome Database
- HMDB0015009
- KEGG Compound
- C07129
- PubChem Compound
- 5403
- PubChem Substance
- 46506887
- ChemSpider
- 5210
- BindingDB
- 25770
- ChEBI
- 9449
- ChEMBL
- CHEMBL1760
- Therapeutic Targets Database
- DAP000246
- PharmGKB
- PA451616
- IUPHAR
- 560
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Terbutaline
- ATC Codes
- R03CC53 — Terbutaline, combinations
- R03CC — Selective beta-2-adrenoreceptor agonists
- R03C — ADRENERGICS FOR SYSTEMIC USE
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- R03AC — Selective beta-2-adrenoreceptor agonists
- R03A — ADRENERGICS, INHALANTS
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- AHFS Codes
- 12:12.08.12 — Selective Beta 2-adrenergic Agonists
- MSDS
- Download (73.1 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Prevention Diabetes, Diabetes Mellitus Type 1 1 2 Completed Treatment Exercised Induced Asthma 1 2, 3 Terminated Treatment External Cephalic Version 1 3 Completed Treatment Acute Exacerbation of Chronic Obstructive Airways Disease / Chronic Obstructive Pulmonary Disease Exacerbation 1 3 Completed Treatment Asthma Bronchial 3 3 Completed Treatment Chronic Obstructive Pulmonary Disease (COPD) 1 4 Completed Treatment Asthma Bronchial 1 4 Completed Treatment Heart Failure, Unspecified 1 4 Completed Treatment Status Asthmaticus 1 4 Recruiting Treatment External Cephalic Version 1 4 Unknown Status Not Available Asthma Bronchial 1 4 Unknown Status Treatment Labour Pain 1 Not Available Completed Basic Science Skeletal Muscle Fatigue in Humans 1 Not Available Completed Treatment Diabetes, Diabetes Mellitus Type 1 1 Not Available Completed Treatment Foetal distress syndrome 1 Not Available Completed Treatment Reproductive Techniques, Assisted 1 Not Available Recruiting Basic Science Muscle Hypertrophy in Healthy Young Men 1
Pharmacoeconomics
- Manufacturers
- Novartis pharmaceuticals corp
- Sanofi aventis us llc
- Aaipharma llc
- Akorn inc
- App pharmaceuticals llc
- Bedford laboratories div ben venue laboratories inc
- Hikma farmaceutica (portugal) sa
- Teva parenteral medicines inc
- Impax laboratories inc
- Lannett holdings inc
- Packagers
- Akorn Inc.
- Amerisource Health Services Corp.
- APP Pharmaceuticals
- AstraZeneca Inc.
- Bedford Labs
- Ben Venue Laboratories Inc.
- Cardinal Health
- Dept Health Central Pharmacy
- Dispensing Solutions
- Gallipot
- Global Pharmaceuticals
- Hikma Pharmaceuticals
- Lannett Co. Inc.
- Mckesson Corp.
- Murfreesboro Pharmaceutical Nursing Supply
- Novartis AG
- Nucare Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Resource Optimization and Innovation LLC
- Rite Aid Corp.
- Teva Pharmaceutical Industries Ltd.
- Tya Pharmaceuticals
- West-Ward Pharmaceuticals
- Dosage forms
Form Route Strength Tablet Oral 2.5 mg Tablet Oral 5 mg Powder, metered Respiratory (inhalation) 0.5 mg Injection Subcutaneous 1 mg/mL Injection, solution Subcutaneous 1 mg/mL Tablet Oral 2.5 mg/1 Tablet Oral 5 mg/1 - Prices
Unit description Cost Unit Terbutaline sulfate powder 38.4USD g Terbutaline Sulfate 1 mg/ml vial 12.99USD vial Terbutaline sulf 1 mg/ml vial 4.8USD ml Brethine 5 mg tablet 0.83USD tablet Terbutaline sulfate 5 mg tablet 0.63USD tablet Brethine 2.5 mg tablet 0.57USD tablet Terbutaline sulfate 2.5 mg tablet 0.47USD tablet Bricanyl Turbuhaler 0.5 mg/dose Metered Inhalation Powder 0.08USD dose DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 119-122 °C Not Available water solubility 213 mg/mL Not Available logP 0.90 TACAKS-NOVAK,K ET AL. (1995) Caco2 permeability -6.38 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 5.84 mg/mL ALOGPS logP 0.55 ALOGPS logP 0.44 ChemAxon logS -1.6 ALOGPS pKa (Strongest Acidic) 8.86 ChemAxon pKa (Strongest Basic) 9.76 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 72.72 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 63.04 m3·mol-1 ChemAxon Polarizability 24.78 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.987 Blood Brain Barrier - 0.9355 Caco-2 permeable - 0.8404 P-glycoprotein substrate Substrate 0.6335 P-glycoprotein inhibitor I Non-inhibitor 0.8954 P-glycoprotein inhibitor II Non-inhibitor 0.9672 Renal organic cation transporter Non-inhibitor 0.9067 CYP450 2C9 substrate Non-substrate 0.7678 CYP450 2D6 substrate Non-substrate 0.7922 CYP450 3A4 substrate Non-substrate 0.6291 CYP450 1A2 substrate Non-inhibitor 0.9516 CYP450 2C9 inhibitor Non-inhibitor 0.9303 CYP450 2D6 inhibitor Non-inhibitor 0.923 CYP450 2C19 inhibitor Non-inhibitor 0.9115 CYP450 3A4 inhibitor Non-inhibitor 0.8766 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9117 Ames test Non AMES toxic 0.9119 Carcinogenicity Non-carcinogens 0.8484 Biodegradation Not ready biodegradable 0.9808 Rat acute toxicity 2.1080 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9548 hERG inhibition (predictor II) Non-inhibitor 0.9467
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as resorcinols. These are compounds containing a resorcinol moiety, which is a benzene ring bearing two hydroxyl groups at positions 1 and 3.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenols
- Sub Class
- Benzenediols
- Direct Parent
- Resorcinols
- Alternative Parents
- Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- Resorcinol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Monocyclic benzene moiety / 1,2-aminoalcohol / Secondary alcohol / Secondary amine / Secondary aliphatic amine / Aromatic alcohol
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- phenylethanolamines, resorcinols (CHEBI:9449)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
- Gene Name
- ADRB2
- Uniprot ID
- P07550
- Uniprot Name
- Beta-2 adrenergic receptor
- Molecular Weight
- 46458.32 Da
References
- Schafers RF, Piest U, von Birgelen C, Jakubetz J, Daul AE, Philipp T, Brodde OE: Disodium cromoglycate does not prevent terbutaline-induced desensitization of beta 2-adrenoceptor-mediated cardiovascular in vivo functions in human volunteers. J Cardiovasc Pharmacol. 1999 May;33(5):822-7. [PubMed:10226872]
- Ramer-Quinn DS, Swanson MA, Lee WT, Sanders VM: Cytokine production by naive and primary effector CD4+ T cells exposed to norepinephrine. Brain Behav Immun. 2000 Dec;14(4):239-55. [PubMed:11120594]
- Zetterlund A, Hjemdahl P, Larsson K: beta2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide. Clin Sci (Lond). 2001 Apr;100(4):451-7. [PubMed:11256987]
- Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T: Activation of beta(2)-adrenoceptor prevents shiga toxin 2-induced TNF-alpha gene transcription. J Am Soc Nephrol. 2001 Nov;12(11):2288-99. [PubMed:11675405]
- Chong LK, Suvarna K, Chess-Williams R, Peachell PT: Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. Br J Pharmacol. 2003 Feb;138(3):512-20. [PubMed:12569076]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Riether C, Kavelaars A, Wirth T, Pacheco-Lopez G, Doenlen R, Willemen H, Heijnen CJ, Schedlowski M, Engler H: Stimulation of beta(2)-adrenergic receptors inhibits calcineurin activity in CD4(+) T cells via PKA-AKAP interaction. Brain Behav Immun. 2011 Jan;25(1):59-66. doi: 10.1016/j.bbi.2010.07.248. Epub 2010 Jul 30. [PubMed:20674738]
- Cooperberg BA, Breckenridge SM, Arbelaez AM, Cryer PE: Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2008 Dec;31(12):2271-2. doi: 10.2337/dc08-0520. Epub 2008 Sep 9. [PubMed:18782903]
- Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [PubMed:1358833]
- Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [PubMed:2062329]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
- Gene Name
- ADRB3
- Uniprot ID
- P13945
- Uniprot Name
- Beta-3 adrenergic receptor
- Molecular Weight
- 43518.615 Da
References
- Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]
- Behr B, Hoffmann C, Ottolina G, Klotz KN: Novel mutants of the human beta1-adrenergic receptor reveal amino acids relevant for receptor activation. J Biol Chem. 2006 Jun 30;281(26):18120-5. Epub 2006 Apr 28. [PubMed:16648137]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Receptor signaling protein activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
- Gene Name
- ADRB1
- Uniprot ID
- P08588
- Uniprot Name
- Beta-1 adrenergic receptor
- Molecular Weight
- 51322.1 Da
References
- Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Kovarik Z, Simeon-Rudolf V: Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline. J Enzyme Inhib Med Chem. 2004 Apr;19(2):113-7. [PubMed:15449725]
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:04